We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Iberdomide-Based Oral Triple Therapy Extends Progression-Free Survival to 17.6 Months in Relapsed Multiple Myeloma: Results from the ICON Study

MedXY Editorial Team•Jan 14, 2026•Hematology-Oncology
multiple myeloma

Highlights

Clinically Meaningful Efficacy

The ICON study demonstrated a median progression-free survival (PFS) of 17.6 months in patients with relapsed and refractory multiple myeloma (RRMM) who were refractory to lenalidomide, a significant outcome for this difficult-to-treat population.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Efficacy and Safety of All-Oral Ixazomib, Pomalidomide, and Dexamethasone in Triple-Class Exposed Multiple Myeloma: Insights from a Phase II StudyThis phase II study evaluates the all-oral ixazomib-pomalidomide-dexamethasone regimen in triple-class exposed relapsed/refractory multiple myeloma patients, demonstrating promising efficacy and manageable safety in an elderly and high-riskSep 18, 2026Leveraging Functional Immune Profiling to Predict Response in Myeloma ImmunotherapyThis study develops a high-content ex vivo assay of T cell dynamics to predict multiple myeloma patient response to bispecific T cell engager therapies, offering a novel functional biomarker for therapy stratification.Sep 18, 2026NF-κB Driven Transcriptional Signatures in CAR-T Cells Predict Durable Responses in Multiple MyelomaSingle-cell transcriptomic profiling of ide-cel CAR-T products reveals that intrinsic NF-κB signaling in CD4 CAR-T cells correlates with durable remission in relapsed/refractory multiple myeloma, marking T-cell fitness and potential therapeSep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis
Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and saf
Sep 13, 2026
Refining Risk Stratification in Newly Diagnosed Multiple Myeloma: Circulating Tumor Cells Identify a Disseminated Genomic High-Risk Phenotype Within IMS-IMWG 2025 StagingCirculating tumor cells (CTCs) enhance the IMS-IMWG 2025 genomic staging by identifying a disseminated high-risk phenotype in newly diagnosed multiple myeloma, improving prognostic stratification and enabling minimally invasive disease moniSep 12, 2026
Arlocabtagene Autoleucel: Advancing Treatment Paradigms in Heavily Pretreated Relapsed/Refractory Multiple MyelomaArlocabtagene autoleucel (arlo-cel) is a novel GPRC5D-targeted CAR T-cell therapy showing promising efficacy and manageable safety in patients with relapsed/refractory multiple myeloma heavily pretreated with standard regimens, including prSep 12, 2026